http://blog.moneta.co.kr/blog.screen?blogId=uhriahn0435 uhriahn0435 ko Copyright ¨Ï ¢ßÆŽº³Ý / SKÅÚ·¹ÄÞ¢ß, All Rights Reserved Sat, 31 Aug 2013 20:12:12 GMT http://blog.moneta.co.kr/blog.log.view.screen?blogId=uhriahn0435&logId=7873375 Increased Affordability and Patient AccessSince Hospira launched its biosimilars, prices have decreased and patient access has increased.In Europe and Australia, biosimilar treatments offer cost savings to healthcare systems of approximately 25 percent to 30 percent.1 In the United States, newer biologic treatments can cost $100,000 or more per patient, per year.2 A price decrease in the United States similar to the one experienced in Europe would benefit patients and payers al... uhriahn0435 Sat, 31 Aug 2013 20:12:12 GMT